title: Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort.
abstract: JC virus (JCV) is an opportunistic virus known to cause progressive multifocal leukoencephalopathy. Anti-JC virus (Anti-JCV) antibody prevalence in a large, geographically diverse, multi-national multiple sclerosis (MS) cohort was compared in a cross-sectional study. Overall, anti-JCV antibody prevalence was 57.6%. Anti-JCV antibody prevalence in MS patients ranged from approximately 47% to 68% across these countries: Norway, 47.4%; Denmark, 52.6%; Israel, 56.6%; France, 57.6%; Italy, 58.3%; Sweden, 59.0%; Germany, 59.1%; Austria, 66.7% and Turkey, 67.7%. Prevalence increased with age (from 49.5% in patients < 30 years of age to 66.5% in patients ≥ 60 years of age; p < 0.0001 comparing all age categories), was lower in females than in males (55.8% versus 61.9%; p < 0.0001) and was not affected by prior immunosuppressant or natalizumab use.
authors: Center for Molecular Medicine, Karolinska Hospital, Stockholm, Sweden.
authors: Tomas
authors: T
authors: Olsson
authors: Anat
authors: A
authors: Achiron
authors: Lars
authors: L
authors: Alfredsson
authors: Thomas
authors: T
authors: Berger
authors: David
authors: D
authors: Brassat
authors: Andrew
authors: A
authors: Chan
authors: Giancarlo
authors: G
authors: Comi
authors: Mefkure
authors: M
authors: Eraksoy
authors: Harald
authors: H
authors: Hegen
authors: Jan
authors: J
authors: Hillert
authors: Poul Erik Hyldgaard
authors: PE
authors: Jensen
authors: Lucia
authors: L
authors: Moiola
authors: Kjell-Morten
authors: KM
authors: Myhr
authors: Annette
authors: A
authors: Oturai
authors: Sven
authors: S
authors: Schippling
authors: Aksel
authors: A
authors: Siva
authors: Per Soelberg
authors: PS
authors: Sorensen
authors: Anne-Kathrin
authors: AK
authors: Trampe
authors: Thomas
authors: T
authors: Weber
authors: James
authors: J
authors: Potts
authors: Tatiana
authors: T
authors: Plavina
authors: Dominic
authors: D
authors: Paes
authors: Meena
authors: M
authors: Subramanyam
authors: Heinz
authors: H
authors: Wiendl
authors: Hussein
authors: H
authors: Dib
authors: Deniz
authors: D
authors: Uren
authors: Bernhard
authors: B
authors: Hemmer
authors: Dorothea
authors: D
authors: Buck
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood*; D002648:Child; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007577:JC Virus / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000097:blood / Q000188:drug therapy / Q000821:virology*; D027601:Polyomavirus Infections / Q000453:epidemiology*; D015995:Prevalence; D017678:Sex Distribution; D055815:Young Adult
chemical_list: D000914:Antibodies, Viral; D007166:Immunosuppressive Agents
keywords: JC virus; Multiple sclerosis; STRATIFY-JCV; anti-JCV antibodies; antibody prevalence; brain infection; epidemiology; immunosuppressant therapy; infection risk; international study; natalizumab